




PHARMACEUTICAL 2021

iBio Inc.
Rank 303 of 402





PHARMACEUTICAL 2021

iBio Inc.
Rank 303 of 402



The relative strengths and weaknesses of iBio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of iBio Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 147% points. The greatest weakness of iBio Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 175% points.

The company's Economic Capital Ratio, given in the ranking table, is -21%, being 69% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	10,304
Cost of Goods Sold	0
Intangible Assets	1,144
Liabilities, Current	5,236
Liabilities, Non-Current	0
Other Assets	27,115
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	32,346
Other Net Income	-2,441
Other Revenues	1,638
Property and Equipment	3,657
Research and Development	3,213
Selling, General and Administrative Expense	12,428

Output Variable	Value in 1000 USD
Assets	42,220
Liabilities	37,582
Expenses	15,641
Revenues	1,638
Stockholders Equity	4,638
Net Income	-16,444
Comprehensive Net Income	-16,444
Economic Capital Ratio	-21%